1. Heart, Lung and Circulation
Novel Oral Anticoagulants in Direct Current Cardioversion for Atrial Fibrillation 
Giuseppe Femia, BSc (Hons), MBBS (Hons), Taufik Fetahovic, MBBS, FRACP, Pratap Shetty, MBBS, MD, FRACP, FCSANZ, Astin Lee, MBBS (Hons), FRCP, FRACP, FCSANZ 
Heart, Lung and Circulation 
DOI: /j.hlc
Copyright © Terms and Conditions

2. Figure 1
Utilisation trends of warfarin, apixaban, dabigatran and rivaroxaban from January 2014 to June 2016.
Heart, Lung and Circulation DOI: ( /j.hlc )
Copyright © Terms and Conditions

3. Figure 2
Utilisation of warfarin and Novel Oral Anticoagulants in relation to CHADSVASc score.
Heart, Lung and Circulation DOI: ( /j.hlc )
Copyright © Terms and Conditions

4. Figure 3
Incidence of Cerebral Vascular Accidents and Major Bleeding Events in Patients Treated with Warfarin and Novel Oral Anticoagulants (NOACs).
Heart, Lung and Circulation DOI: ( /j.hlc )
Copyright © Terms and Conditions

5. Figure 4
Incidence of Cerebral Vascular Accidents and Major Bleeding Events in Patients Treated with Short Duration (<5 days) or Long Duration (>5 days) Novel Oral Anticoagulant (NOAC) Therapy.
Heart, Lung and Circulation DOI: ( /j.hlc )
Copyright © Terms and Conditions